Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
about
Evaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistancesUrinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric studyRationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.The importance of total kidney volume in evaluating progression of polycystic kidney diseaseUrinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development.Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney diseaseUrinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study.Predictors of autosomal dominant polycystic kidney disease progressionADPKD: Prototype of Cardiorenal Syndrome Type 4Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney diseaseUrinary biomarkers at early ADPKD disease stageUrine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney DiseaseIncreased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction.Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting.Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1.Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseasesUrine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline.Urinary MCP1 and Microalbumin increase prior to onset of Azotemia in mice with polycystic kidney disease.Renal biomarkers of kidney injury in cardiorenal syndrome.Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.Neutrophil gelatinase associated lipocalin in acute kidney injury.Urinary Renin-Angiotensin Markers in Polycystic Kidney Disease.Clinical Trials and a View Toward the Future of ADPKD.Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.Diagnostic Evaluation as a Biomarker in Patients with ADPKD.Insights into autosomal dominant polycystic kidney disease by quantitative mass spectrometry-based proteomics.Biomarkers for the early detection of acute kidney injury.Do neutrophil gelatinase-associated lipocalin and interleukin-18 predict renal dysfunction in patients with familial Mediterranean fever and amyloidosis?New treatment paradigms for ADPKD: moving towards precision medicine.Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease.Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.
P2860
Q28084462-B578CF45-EE91-4B22-947F-208BBA5C4800Q28484968-ECF8F3FC-1B94-433F-88F7-6C01ED993AEAQ33702355-D3F48D4E-2507-42EA-916E-1A4D9B7D74AEQ33873107-209DCC18-A478-4E59-A6C2-F920889F44EBQ33887958-4D31A4AB-D5E3-4253-B4E6-A90EB9621185Q34220059-29642515-B4C9-457E-8330-1AF7D4BEADDBQ34398335-1F8938D9-FD73-402E-BA16-4DD8E38E06DDQ34427678-D13E42D0-7578-46B3-A92A-09363339495DQ34475590-AF75DE35-67D9-4CD1-A09C-A86AB5C0A037Q35126716-0B6D73DE-FF2F-40DB-B6E5-8171A740A8DFQ35392624-2923D840-B5A8-441D-A953-F79652E5BFB8Q35559202-F5C419E8-3C8F-4036-A912-36C1A7DAB188Q35658562-F41D8845-CD1B-44A6-9827-E57FE8A8076BQ35669323-DAC05A7F-573D-44C5-8EEA-6CB3519E7AF9Q35799748-99575E42-B0B2-4A22-A9DD-8CAEDC2793C6Q35928981-BB28C1FF-CEB2-46E6-AAD0-70845FDD20DBQ35938697-BE12BA14-3CD9-4915-9954-A84E8F385325Q36025651-539A4D21-5CDB-4295-95D6-D503B4794DE0Q37075292-C529F2FA-E1DA-49D7-A02A-555B09F2F9BFQ37107248-50508005-7C45-4841-9D23-4423A96C338AQ37529560-500A079A-AB39-4A61-93AC-D25F418137E7Q37719437-097E7868-4C0A-4261-B452-BA4AFDD32BA2Q37850384-330FF3E2-A3B1-4FBA-9702-200AAC32BDCBQ38030726-DD038F96-74FE-4997-90CF-BFF8CEC54C76Q38160639-C432EFE9-BE6B-470E-B2CF-B5AA7AEB401DQ38651399-6023B14C-D90F-4097-84E9-622C577792E6Q38812543-9FBBD54E-9516-45B9-BB61-0D3C45865921Q38960067-F17791BA-AB98-489C-97C1-4D69A491CC5EQ38978474-4307DD18-42AC-498E-A193-474E4A923A72Q39255681-852BCD3B-D20D-408E-9344-8F03165D4E38Q39791593-BDD64553-1EE8-4BD1-A45C-1A622FC414D1Q40225567-8A209DFA-6EE7-421A-A873-18EB472AAC0CQ49494721-1A6F146E-769A-4495-857F-3CF7AB3466DFQ51284455-8AEB8A2F-F34C-4DAA-8605-7682B8B85643Q51735152-A5433A31-E69B-417D-8C24-834809BF7502Q52850208-5A588D42-E998-4E1B-8AA6-1F142C44300FQ53035502-99749ADE-81CC-4AAB-A81C-DB2D7D922834Q54540098-EEBBBA6F-9A67-4DEC-8C4E-493D30BB0B77Q55363555-C3EDB13E-9457-4E51-B976-4632F88A2DB5
P2860
Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Association of urinary biomark ...... e: a cross-sectional analysis.
@en
Association of urinary biomark ...... e: a cross-sectional analysis.
@nl
type
label
Association of urinary biomark ...... e: a cross-sectional analysis.
@en
Association of urinary biomark ...... e: a cross-sectional analysis.
@nl
prefLabel
Association of urinary biomark ...... e: a cross-sectional analysis.
@en
Association of urinary biomark ...... e: a cross-sectional analysis.
@nl
P2093
P1476
Association of urinary biomark ...... e: a cross-sectional analysis.
@en
P2093
Dorien J M Peters
Eric J van der Jagt
Esther Meijer
Ferdau L Nauta
Gerjan Navis
Harry van Goor
Mieneke Rook
Paul E de Jong
Ron T Gansevoort
Stephan J L Bakker
P304
P356
10.1053/J.AJKD.2010.06.023
P577
2010-11-01T00:00:00Z